Navafenterol,a new drug for the treatment of chronic obstructive air-way disease
10.12092/j.issn.1009-2501.2024.04.006
- VernacularTitle:一种治疗慢性阻塞性气道疾病的新药:那伐芬特罗
- Author:
Yuru LIU
1
;
Wenwen WU
;
Gang WANG
Author Information
1. 四川大学华西医院呼吸与危重症医学科呼吸疾病临床医学研究中心,成都 610041,四川;呼吸和共病全国重点实验室,成都 610041,四川
- Keywords:
navafenterol;
chronic obstructive pul-monary disease;
asthma;
bronchodilator;
muscarin-ic receptor antagonist;
β2 receptor agonist
- From:
Chinese Journal of Clinical Pharmacology and Therapeutics
2024;29(4):401-405
- CountryChina
- Language:Chinese
-
Abstract:
Navafenterol is a new compound with both muscarinic receptor antagonist and β2 recep-tor agonist effects in a single molecule,who is be-ing developed for the treatment of chronic obstruc-tive airway disease such as chronic obstructive pul-monary disease and asthma.These pilot clinical studies found that it can significantly improve lung function and symptoms,and is safe and well toler-ated.Common treatment emergent adverse events include headache,nasopharyngitis,and dizziness.It may become a next-generation bronchodilator for chronic obstructive airway disease.This review introduced the prospective of Navafenterol.
